Anti-PD-1 antibodies and methods of use thereof

US10450373B2 · kind B2 · utility

Assignees

• Agenus Inc. · US
• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB
• Memorial Sloan Kettering Cancer Center · US

Inventors

• Marc van Dijk · Bosch en Duin, NL
• Cornelia Anne Mundt · Lörrach, DE
• Gerd Ritter · New York, US
• Jedd D. Wolchok · New York, US
• Taha Merghoub · New York, US
• Roberta Zappasodi · New York, US
• Rikke Baek HOLMGAARD · New York, US
• David Schaer · Mamaroneck, US
• David Adam Savitsky · Boxford, US
• Nicholas Stuart Wilson · Melbourne, AU

Key dates

• Filing date: Apr 30, 2019
• Grant date: Oct 22, 2019
• Expiry date: Apr 30, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.